Survival in patients with clear cell renal cell carcinoma is predicted by HIF-1α expression

Anticancer Research

Volumn 35, Issue 1, 2015, Pages 433-438

  Minardi, Daniele ^a   Lucarini, Guendalina ^a   Santoni, Matteo ^a   Mazzucchelli, Roberta ^b   Burattini, Luciano ^a   Conti, Alessandro ^a   Principi, Emanele ^a   Bianconi, Maristella ^a   Scartozzi, Mario ^a   Milanese, Giulio ^a   Di Primio, Roberto ^a   Montironi, Rodolfo ^b   Cascinu, Stefano ^a   Muzzonigro, Giovanni ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

Clear cell renal cell carcinoma; Hypoxia inducible factor; Overall survival; Tumor grade; Tumor stage

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HIF1A PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; KIDNEY NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEPHRECTOMY; PROPORTIONAL HAZARDS MODELS;

EID: 84920482790     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55 (2): 74-108, 2005.
2. Chow WH, Devesa SS, Warren JL and Fraumeni JF: Rising incidence of renal cell cancer in the United States. JAMA 281 (17): 1628-1631, 1999.
3. Hock LM, Lynch J and Balaji KC: Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of Surveillance, Epidemiology and End Results program data. J Urol 167 (1): 57-60, 2002.
4. Zhou Y, Lin L, Wang Y, Jin X, Zhao X, Liu D, Hu T, Jiang L, Dan H, Zeng X, Li J, Wang J and Chen Q: The association between hypoxia-inducible factor-1 α gene G1790A polymorphism and cancer risk: a meta-analysis of 28 case-control studies. Cancer Cell International 14 (37): 1-11, 2014.
5. Pharoah PD, Dunning AM, Ponder BA and Easton DF: Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4 (11): 850-860, 2004.
6. Ruan K, Song G and Ouyang G: Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 107 (6): 1053-1062, 2009.
7. Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2 (1): 8-47, 2002.
8. Dery MA, Michaud MD and Richard DE: Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37 (3): 535-540, 2005.
9. Wang GL and Semenza GL: Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270 (3): 1230-1237, 1995.
10. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ and Banks RE: Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 15 (24): 7582-7592, 2009.
11. Shen C and Kaelin WG Jr.: The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 23 (1): 18-25, 2013.
12. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ and Belldegrun AS: Hypoxia-Inducible Factor 1A in Clear Cell Renal Cell Carcinoma. Clin Cancer Res 13 (24): 7388-7393, 2007.
13. Wang X, Liu Y, Ren H, Yuan Z, Li S, Sheng J, Zhao T, Chen Y, Liu F, Wang F, Huang H and Hao J: Polymorphisms in the hypoxia-inducible factor-1alpha gene confer susceptibility to pancreatic cancer. Cancer Biol Ther 12 (5): 383-387, 2011.
14. Mera-Menendez F, Hinojar-Gutierrez A, Guijarro RM, de Gregorio JG, Mera-Menendez E, Sanchez JJ, Quintanilla M, Cerezo L and Gamallo C: Polymorphisms in HIF-1alpha affect presence of lymph node metastasis and can influence tumor size in squamous-cell carcinoma of the glottis larynx. Clin Transl Oncol 15 (5): 358-363, 2013.
15. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG Jr and Pavletich NP: Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science 296 (5574): 1886-1889, 2002.
16. Munoz-Guerra MF, Fernandez-Contreras ME, Moreno AL, Martin ID, Herraez B and Gamallo C: Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. Ann Surg Oncol 16 (8): 2351-2358, 2009.
17. Frank B, Hoffmeister M, Klopp N, Illig T, Chang-Claude J and Brenner H: Single nucleotide polymorphisms in Wnt signaling and cell death pathway genes and susceptibility to colorectal cancer. Carcinogenesis 31 (8): 1381-1386, 2010.
18. Konac E, Onen HI, Metindir J, Alp E, Biri AA and Ekmekci A: An investigation of relationships between hypoxia-inducible factor-1 alpha gene polymorphisms and ovarian, cervical and endometrial cancers. Cancer Detect Prev 31 (2): 102-109, 2007.
19. Naidu R, Har YC and Taib NA: Associations between hypoxiainducible factor-1alpha (HIF-1alpha) gene polymorphisms and risk of developing breast cancer. Neoplasma 56 (5): 441-447, 2009.
20. Hsiao PC, Chen MK, Su SC, Ueng KC, Chen YC, Hsieh YH, Liu YF, Tsai HT and Yang SF: Hypoxia inducible factor-1alpha gene polymorphism G1790A and its interaction with tobacco and alcohol consumptions increase susceptibility to hepatocellular carcinoma. J Surg Oncol 102 (2): 163-169, 2010.
21. Kim YH, Park IA, Park WY, Kim JW, Kim SC, Park NH, Song YS and Kang SB: Hypoxia-inducible factor 1alpha polymorphisms and early-stage cervical cancer. Int J Gynecol Cancer 21 (1): 2-7, 2011.
22. Fransen K, Fenech M, Fredrikson M, Dabrosin C and Soderkvist P: Association between ulcerative growth and hypoxia inducible factor-1alpha polymorphisms in colorectal cancer patients. Mol Carcinog 45 (11): 833-840, 2006.
23. Fuhrman SA, Lasky LC and Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6 (7): 655-663, 1982.
24. Sobin LH and Witteking CH: TNM classification of malignant tumours, 6th ed. New York: Wiley-Liss; 2002.
25. Kondo K, Klco J, Nakamura E, Lechpammer M and Kaelin WG Jr: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (3): 237-246, 2002.
26. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM and Klausner RD: The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (3): 247-255, 2002.
27. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J and Ljungberg B: The expression of hypoxia inducible factor 1a is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 11 (3): 1129-1135, 2005.
28. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Bergh A and Ljungberg B: Hypoxia-inducible factor 1a expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol 50 (6): 1272-1277, 2006.
29. Lessi F, Mazzanti CM, Tomei S, Di Cristofano C, Minervini A, Menicagli M, Apollo A, Masieri L, Collecchi P, Minervini R, Carini M and Bevilacqua G: VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma. Med Oncol 31 (3): 840, 2014.
30. Lam JS, Shvarts O, Leppert JT, Figlin RA and Belldegrun AS: Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173 (6): 1853-1862, 2005.
31. Maroto P and Rini B: Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res 20 (8): 2060-2071, 2014.
32. Weiss RH, BorowskyAD, Seligson D, Lin PY, Dillard-Telm L, Belldegrun AS, Figlin RA and Pantuck AD: p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol 177 (1): 63-68, 2007.
33. Redell MS and Tweardy DJ: Targeting transcription factors for cancer therapy. Curr Pharm Des 11 (22): 2873-2887, 2005.
34. Chang Q, Qin R, HuangT, Gao J and Feng Y: Effect of antisense hypoxia-inducible factor 1aon progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas 32 (3): 297-305, 2006.
35. Minardi D, Lucarini G, Filosa A, Milanese G, Zizzi A, Di Primio R, Montironi R and Muzzonigro G: Prognostic role of tumor necrosis, microvessel density (MVD), vascular endothelial growht factor (VEGF) and hypoxia inducile factor-1α (HIF-1α) in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Intern J Immunopathol Pharmacol 21 (2): 447-455, 2008.
36. Kluger HM, Siddiqui SF, Angeletti C, Sznol M, Kelly WK, Molinaro AM and Camp RL: Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells. Lab Invest 88 (9): 962-972, 2008.
37. Minardi D, Lucarini G, Santoni M, Mazzucchelli R, Burattini L, Pistelli M, Bianconi M, Di Primio R, Scartozzi M, Montironi R, Cascinu S and Muzzonigro G: VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. Anticancer Res 33 (11): 5017-5022, 2013.
38. Santoni M, Santini D, Massari F, Conti A, Iacovelli R, Burattini L, Tortora G, Falconi M, Montironi R and Cascinu S: Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer Metastasis Rev 33 (1): 321-331, 2014.